Bristol Myers Strikes Up To $2.3B Avidity Cardio Partnership
Bristol Myers Squibb has struck a research partnership with Avidity Biosciences Inc. that could see the biopharmaceutical giant funnel up to $2.3 billion into the discovery, development and commercialization of certain treatments for cardiovascular...To view the full article, register now.
Already a subscriber? Click here to view full article